Conavi Medical Corp. Announces Closing of $12M Public Offering

Executive Summary

• Conavi Medical Corp. closed its previously announced equity offering, raising approximately $12 million in gross proceeds.
• The offering consisted of 26,666,670 common shares sold at $0.45 per share.
• Net proceeds will be used to obtain U.S. FDA 510(k) clearance for the next‑generation Novasight Hybrid system, fund a targeted U.S. market release, and provide working capital/general corporate purposes.

Key Details

• Offering Size: Gross proceeds of $12,000,001.50 from sale of 26,666,670 common shares at $0.45 each.
• Agent Compensation: Bloom Burton Securities Inc. received a cash commission of $701,479.49 and 1,558,843 compensation options (each option allows purchase of one common share at $0.45, expiring Jan 13 2028).
• Use of Proceeds:
• Obtain U.S. FDA 510(k) clearance for the next‑generation Novasight Hybrid intravascular imaging system.
• Initiate a targeted market release of Novasight in the United States.
• Provide working capital and other general corporate purposes.
• Regulatory Structure: Shares were sold under an amended and restated short‑form prospectus (filed Jan 7 2026) for Canadian investors and via private placement exemptions for U.S. investors; no registration under the U.S. Securities Act.
• CEO Quote: “This Offering positions Conavi to initiate a targeted market release of Novasight, following U.S. FDA clearance… The proceeds will support our commercialization efforts and continued advancement of our intravascular imaging platform.” – Tom Looby, President & CEO.

Notable Quotes

“The strong participation from U.S. strategic healthcare investors reflects confidence in our technology and commercial strategy, as well as growing interest in intravascular imaging technologies.” – Tom Looby, President and Chief Executive Officer.